Market Intelligence, Early-Stage Pipeline Trends, and High-Purity Reagents for Transcription Factor Drug Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BACH2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Full-Length & Domains) | BACH2 Recombinant Protein (WT/Mutant) including BTB (1–130 aa) and bZIP domains; high purity (>95%), endotoxin <1 EU/µg, sequence verified. Ideal for PROTAC & small molecule screening. | View BACH2 Products |
| Gene Delivery | BACH2 Lentivirus Particles (full-length ORF, FLAG-tag, titer >1e8 TU/mL) for stable reporter cell lines and nuclear localization studies. | View BACH2 Products |
| Benchmark Ab | Anti-BACH2 Recombinant Antibody (ChIP-grade, validated for BTB recognition) as positive control for WB, IHC, ChIP, and flow cytometry. | View BACH2 Products |
| Validator | BACH2 siRNA Set (3 target-specific + scrambled control; >70% knockdown) for specificity verification and endogenous knockdown. | View BACH2 Products |
| Related Target: BACH1 | BACH1 Recombinant Protein & Antibody for selectivity counter-screening; close paralog in BTB-bZip family. | View BACH1 Products |
| Related Target: MAFK | MAFK Recombinant Protein; essential small Maf heterodimer partner for EMSA and dimerization disruption assays. | View MAFK Products |
| Related Target: PDCD1 (PD-1) | PD-1 Protein & Antibody; synergistic target as BACH2 regulates T cell exhaustion and PD-1 expression. | View PDCD1 Products |
| Related Target: FOXP3 | FOXP3 Protein & Antibody; key Treg marker intricately modulated by BACH2 networks. | View FOXP3 Products |
| Related Target: MAF | MAF Recombinant Protein; critical heterodimeric partner for BACH2 DNA binding and transcriptional regulation. | View MAF Products |
| Related Target: BATF | BATF Recombinant Protein; competing AP-1 family member; functional antagonist in Treg/Th17 differentiation assays. | View BATF Products |
| Related Target: IRF4 | IRF4 Recombinant Protein; cooperative transcription factor required for BACH2-mediated plasma cell differentiation. | View IRF4 Products |
Critical Assay Challenges & TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity vs. paralog BACH1 | Human BACH1 & BACH2 proteins (>95% purity, mass spec verified) for clean counter-screening. |
| Cell-based target engagement / Intracellular target (PROTAC/Small Molecule Binding) | Premade lentivirus particles for stable BACH2 overexpression/knockdown reporter lines; high-purity His/GST-tagged recombinant proteins optimized for TR-FRET/AlphaScreen. |
| Lack of specific positive controls (ChIP, WB, IC) | Sequence-verified anti-BACH2 recombinant antibody for precise target engagement validation. |
| False positives in DNA-binding or pathway assays | Custom DNA-binding deficient BACH2 mutant proteins available; validated siRNA set for endogenous knockdown confirmation. |
| Nuclear transcription factor solubility / BTB domain dimerization | HEK293-expressed full-length BACH2 with optimized detergent buffers; isolated BTB domain (1–130 aa) with verified homodimer interface for SPR/AlphaScreen PPI assays. |
| DNA binding specificity (Maf recognition) | BACH2-bZIP domain fused to GST for EMSA/FP assays; sequence verified binding to MARE. |
Key Mutations & Disease Relevance
- IMD60 mutations (UniProt VAR_082216, VAR_082217): Impair protein stability (mutant insoluble, forms multiple aggregates) and severely decrease nuclear localization. Critical for functional studies and dominant-negative assay controls.
- rs34335140 (UniProt VAR_033535): A common SNP in BACH2; relevant for population genetics and disease association studies in autoimmune disorders.
Live BACH2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Discovery Research & Inhibitor Studies
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
BACH2 (BTB and CNC homology 1, basic leucine zipper transcription factor 2) is a master regulator of immune cell fate decisions, balancing regulatory T cell (Treg) versus effector T cell differentiation. The global pipeline remains in early discovery and preclinical stages, with increasing interest from targeted protein degradation (PROTAC/molecular glue) and small-molecule inhibitor programs. Key indications span autoimmune diseases (multiple sclerosis, type 1 diabetes, inflammatory bowel disease) and B-cell malignancies (DLBCL, ALL) where BACH2 functions as a tumor suppressor. The next wave of R&D emphasizes paralog-selective engagement (BACH1 vs. BACH2), cell-permeant probe development, and combination strategies with checkpoint inhibitors to overcome the traditional undruggable barriers of nuclear transcription factors. Emerging modalities include ex vivo gene editing (CRISPR) in CAR-T cells to enhance memory persistence, and molecular glues that disrupt BTB-mediated homodimerization.
Competitive Modality & Indication Snapshot
| Modality | Representative Players / Focus | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors / PPI | Discovery biotechs, academic consortia | Autoimmune disease, B-cell malignancies | Cell-free DNA-binding & dimerization assays (need purified WT and mutant BACH2 domains) |
| PROTAC / Molecular Glue | TPD-focused biotechs (C4 Therapeutics, Monte Rosa, Arvinas-type platforms) | Relapsed/refractory lymphoma, refractory autoimmunity | Target engagement & ternary complex formation (need high-purity full-length BACH2, BACH1, & MAFK proteins) |
| Peptide / Degrader Conjugates | Emerging biotech platforms | Solid tumor immune modulation | Intracellular stability & delivery assays (need recombinant antibodies for ChIP/IC validation) |
| Cell Therapy (CAR-T/TCR-T) | Academic/biotech | Refractory cancers | Gene overexpression/knockdown (need lentivirus & siRNA for functional rescue) |
| Gene Editing (CRISPR) | Editas, Intellia | Primary immunodeficiencies | Functional rescue assay (need mutant BACH2 proteins for dominant negative validation) |